Related references
Note: Only part of the references are listed.Structural elucidation of two novel degradants of lurasidone and their formation mechanisms under free radical-mediated oxidative and photolytic conditions via liquid chromatography-photodiode array/ultraviolet-tandem mass spectrometry and one-dimensional/two-dimensional nuclear magnetic resonance spectroscopy
Kathy Cheng Wang et al.
JOURNAL OF MASS SPECTROMETRY (2022)
Identification of degradation products in flumazenil using LC-Q-TOF/MS and NMR: Degradation pathway elucidation
Jing Jiang et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2022)
Development and Validation of RP-HPLC Method for Estimation of Lurasidone and its impurities Lurasidone 1 and Lurasidone 8
Maulikkumar D. Vaja et al.
Research Journal of Pharmacy and Technology (2022)
Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature
William M. Greenberg et al.
CLINICAL PHARMACOKINETICS (2017)
Identification and characterization of process-related substances and degradation products in apremilast: Process optimization and degradation pathway elucidation
Yuting Lu et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2017)
Development of a validated high-performance liquid chromatographic method for the determination of Lurasidone in pharmaceuticals
Sakine Atila Karaca et al.
MARMARA PHARMACEUTICAL JOURNAL (2017)
LC-MS/MS assay for the determination of lurasidone and its active metabolite, ID-14283 in human plasma and its application to a clinical pharmacokinetic study
Mahitej Yadav Katteboina et al.
BIOMEDICAL CHROMATOGRAPHY (2016)
Identification and characterization of related substances in pomalidomide by hyphenated LC-MS techniques
Ping Lu et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2015)
Structural characterization of alkaline and oxidative stressed degradation products of lurasidone using LC/ESI/QTOF/MS/MS
M. V. N. Kumar Talluri et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2015)
Enantioselective Synthesis of ((1R,2R)-Cyclohexane-1,2-diyl)bis(methylene)dimethanesulfonate, a Lurasidone Hydrochloride Intermediate
K. Ravi Ganesh et al.
SYNTHETIC COMMUNICATIONS (2015)
The use of dried blood spots for quantification of 15 antipsychotics and 7 metabolites with ultra-high performance liquid chromatography - tandem mass spectrometry
Lisbeth Patteet et al.
DRUG TESTING AND ANALYSIS (2015)
The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia
Frank I. Tarazi et al.
EXPERT OPINION ON DRUG DISCOVERY (2013)
Forced degradation and impurity profiling: Recent trends in analytical perspectives
Deepti Jain et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2013)
A Sensitive and Selective LC-MS Method for the Determination of Lurasidone in Rat Plasma, Bile, and Urine
Yoon-Jee Chae et al.
CHROMATOGRAPHIA (2012)
Quantification of lurasidone, an atypical antipsychotic drug, in rat plasma with high-performance liquid chromatography with tandem mass spectrometry
Tae-Sung Koo et al.
BIOMEDICAL CHROMATOGRAPHY (2011)
Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats
Kyeong-Ryoon Lee et al.
XENOBIOTICA (2011)
Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A Receptor Activity
Tadashi Ishibashi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Share Paper
